Researchers at Imperial College London in the UK found that the 'romantic' hormone - kisspeptin - can enhance activity in brain regions associated with sexual arousal and romantic love.
"Our study shows that kisspeptin boosts sexual and romantic brain activity as well as decreasing negative mood," said Alexander Comninos from Department of Medicine at Imperial.
"This raises the interesting possibility that kisspeptin may have uses in treating psychosexual disorders and depression which are major health problems which often occur together, but further studies would be needed to investigate this," said Comninos.
In an MRI scanner the men were shown a variety of images, including sexual and non-sexual romantic pictures of couples, whilst researchers scanned their brains to see how kisspeptin affected the brain's responses.
Researchers found that after the injection of kisspeptin, when the volunteers were shown sexual or romantic images of couples, there was enhanced activity in structures in the brain typically activated by sexual arousal and romance.
They believe this shows kisspeptin boosts behavioural circuits associated with sex and love. They are particularly interested in how kisspeptin might be able to help people with psychosexual disorders and related problems with conceiving a baby.
"These of course play a huge part in reproduction, but the role that the brain and emotional processing play in this process is also very important, and only partially understood," said Dhillo.
As the research is at an early stage, the researchers now want to do a follow on study to analyse the effects of kisspeptin in a larger group, including women as well as men.
Kisspeptin did not appear to alter emotional brain activity in response to neutral, happy or fearful-themed images.
However, when volunteers were shown negative images, kisspeptin did enhance activity in brain structures important in regulating negative moods and study participants reported a reduction in negative mood in a post-scan questionnaires.
The study was published in the Journal of Clinical Investigation.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
